[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anovulation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anovulation":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,58],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100605235","letrozole-extended-vs-traditional-therapy-for-ovulation-induction-in-women-with-pcos-prolex-pcos-100605235",false,"NCT07159880","Letrozole Extended vs Traditional Therapy for Ovulation Induction in Women With PCOS (PROLEx-PCOS)","Extended Therapy Versus Traditional Therapy With Letrozole for Ovulation Induction in Women With Polycystic Ovary Syndrome: A Randomized Controlled Trial","PROLEx-PCOS","Inclusion Criteria:\n\n* Women aged 18 to 40 years;\n* BMI between 18,5 and 31 kg\u002Fm2\n* Diagnosis of Polycystic Ovary Syndrome (PCOS) according to the Rotterdam criteria (2003) (presence of at least two of the following: oligo\u002Fanovulation, clinical and\u002For biochemical hyperandrogenism, polycystic ovarian morphology on ultrasound);\n* Active desire for pregnancy at the time of enrollment;\n* Ability and willingness to provide written informed consent (ICF).\n\nExclusion Criteria:\n\n* Age \\\u003C18 or \\>40 years;\n* Presence of confirmed bilateral tubal factor, severe male factor infertility, premature ovarian insufficiency, uncontrolled hyperprolactinemia or thyroid dysfunction);\n* Congenital or acquired uterine malformations;\n* History of gynecologic or breast cancer;\n* Known hypersensitivity to, or contraindication for, letrozole;\n* Severe uncontrolled systemic disease (e.g., cardiovascular, renal, or hepatic disorders);\n* Pregnancy or breastfeeding at the time of screening.",true,"FEMALE","18 Years","40 Years",{"count":22,"type":23},20,"ESTIMATED","INTERVENTIONAL",[26],"NA","This randomized clinical trial aims to compare the efficacy and safety of extended letrozole therapy (5 mg\u002Fday for 10 days) versus standard letrozole therapy (5 mg\u002Fday for 5 days) for ovulation induction in women with polycystic ovary syndrome (PCOS). A total of 84 women aged 18-40 years will be randomized into two groups. Ovulation will be monitored by transvaginal ultrasound and confirmed with urinary LH testing and\u002For corpus luteum presence. The primary outcome is ovulation rate, while secondary outcomes include number and size of mature follicles, clinical pregnancy rate, multiple pregnancy rate, miscarriage rate, number of cycles until pregnancy, and incidence of ovarian hyperstimulation syndrome (OHSS).",[29,30,31],"PCOS (Polycystic Ovary Syndrome)","Infertility","Anovulation",[33,34,35,36,37,38,39,40,41,42,43,44],"polycystic ovary syndrome","PCOS","Ovulation induction","Letrozole","Aromatase Inhibitor","Extended letrozole therapy","traditional letrozole therapy","standart letrozole therapy","infertility","anovulation","ovulation rate","pregnancy rate","RECRUITING","2025-11-23",{"date":48,"type":49},"2025-11-28","ACTUAL",{"date":51,"type":49},"2025-09-01",{"date":53,"type":23},"2026-07-30",{"name":55,"class":56},"GABRIEL MONTEIRO PINHEIRO","OTHER",1,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":4,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":65,"targetDuration":4,"studyType":24,"phases":67,"briefSummary":68,"conditions":69,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100412463","effect-of-vitamin-d-on-ovulation-rate-in-women-with-polycystic-ovary-syndrome-100412463","NCT04650880","Effect of Vitamin D on Ovulation Rate in Women With Polycystic Ovary Syndrome","A Randomized Double-blind Controlled Trial on the Effect of Vitamin D on Ovulation Rate of Women With Polycystic Ovary Syndrome","Inclusion Criteria:\n\n* Premenopausal\n* Aged 18-40 years\n* Irregular long menstrual cycles (\\>35 days)\n* PCOS according to the Rotterdam criteria\n* Agree for transvaginal ultrasound\n\nExclusion Criteria:\n\n* Use of hormonal medication (including contraception) within 3 months prior to study inclusion, except the use of a progestogen to induce withdrawal bleeding every 3 months\n* History of any medical condition or medications that may predispose to vitamin D sensitivity, altered vitamin D metabolism and\u002F or hypercalcemia, including active tuberculosis or current therapy for tuberculosis, sarcoidosis, history of renal\u002F ureteral stones, parathyroid disease, renal or liver failure or current use of anti-convulsants\n* Use of insulin-sensitizing drugs, lipid lowering drugs or anti-hypertensive\n* Anticipated to use the above medications in the coming one year\n* Known type 2 diabetes mellitus\n* Refusal to join the study\n* Abnormal blood calcium level\n\nFor those on supplements, we asked them to stop their own supplements.",{"count":66,"type":23},220,[26],"This is a randomized double-blind controlled trial on the effect of vitamin D supplementation to assess the ovulation rate of women with polycystic ovary syndrome (PCOS) and other reproductive, endocrine and metabolic outcomes after one year of treatment.",[70,31],"Polycystic Ovary Syndrome","2024-05-13",{"date":73,"type":49},"2024-05-14",{"date":75,"type":49},"2021-01-26",{"date":77,"type":23},"2026-12-31",{"name":79,"class":56},"The University of Hong Kong",3]